Boston Scientific to acquire California firm treating irregular heartbeats
Photo | Courtesy Boston Scientific
Boston Scientific headquarters in Marlborough
Expanding its portfolio further into cardiovascular health, Marlborough medical device manufacturer Boston Scientific has entered into a definitive agreement to acquire Cortex, a California medical technology company working to advance the treatment of atrial fibrillation.
Through the acquisition, Boston Scientific will gain ownership of Cortex’s OptiMap System, a diagnostic mapping tool used in cardiac ablation for atrial fibrillation treatment. The system utilizes a basket catheter and proprietary algorithm in order to analyze the heart, allowing providers to target potential active atrial fibrillation sources, according to a Monday press release from Boston Scientific.
Boston Scientific is not disclosing the deal terms or purchase price of the acquisition, according to an email sent to WBJ.
“We look forward to advancing this technology and driving future clinical evidence generation with the goal of making it accessible to physicians and patients globally in the years ahead," Nick Spadea-Anello, global president of electrophysiology at Boston Scientific, said in the release.
Cortex’s OptiMap System received U.S. Food and Drug Administration 510k clearance in 2023. An 510k clearance means the FDA has determined the device is equivalent to another already in commercial distribution and thus able to legally market the device in the U.S., according to the FDA’s website. Earlier in 2024, Cortex initiated a global clinical trial of 300 patients assessing the effectiveness of its OptiMap System.
"Cortex was established to provide physicians with a more intelligent and precise solution for patients with AF," Duke Rohlen, CEO of Cortex, said in the release. "Joining Boston Scientific will allow us to further develop this technology, which we believe has the ability to transform the treatment of AF for patients around the world."
Boston Scientific’s latest acquisition comes as the manufacturer closed its $1.18-billion acquisition of California medical device maker Silk Road Medical in September.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare and diversity, equity, and inclusion industries.
0 Comments